UPDATE: Bank of America Downgrades Optimer Pharmaceuticals to Underperform on Outlook
Bank of America lowered its rating on Optimer Pharmaceuticals (NASDAQ: OPTR) from Buy to Underperform and reduced its price objective from $18 to $15.
Bank of America commented, "Lowering peak penetration estimates following a slowdown in Dificid script trends and feedback from the recent ICAAC conference, we have a more cautious outlook for Dificid in Clostridium difficile infections (CDI). We lowered our projected peak penetration in hospitals from 25% to 20%, in line with our estimate for LTC facilities, which may still be aggressive. The recent new technology add-on payment assigned to Dificid by CMS could encourage more hospital use, but is not enough to offset our current concerns."
Optimer Pharmaceuticals closed at $15.75 on Monday.
Latest Ratings for OPTR
|Jul 2013||Canaccord Genuity||Downgrades||Buy||Hold|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.